8 unknown, 2 completed, 1 not yet recruiting, 1 recruiting. 12 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Unknown 8, Completed 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 7 | Unknown 4, Completed 1, Not yet recruiting 1, Recruiting 1 |
Follow SHR-1701: new trials by email Literature Review of SHR-1701 trials Research Report on SHR-1701
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Metastatic PDAC SHR-1701, Apatinib, gemcitabine - Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | West China Hospital | 45 | 2026-09-21 | 2026-11-09 |
| SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma SHR2554+ SHR1701, SHR-1701 - Relapsed or Refractory Hodgkin Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 100 | 2023-06-14 | 2023-06-15 |
| Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer Almonertinib combined with SHR-1701, Almonertinib - Relapsed or Advanced Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 160 | 2022-10-01 | 2022-08-17 |
| A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection - Advanced Malignant Tumors | Phase 1 | Unknown | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 240 | 2022-02-22 | 2022-06-28 |
| SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma SHR-1701, Famitinib - Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 30 | 2021-09-01 | 2021-08-25 |
| A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors SHR-1701, Famitinib - Solid Tumor | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 222 | 2021-03-17 | 2022-01-26 |
| A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer SHR-1701 - Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 56 | 2020-11-24 | 2024-01-11 |
| Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas SHR2554+SHR1701, SHR1701 - Solid Tumor, Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 100 | 2020-09-01 | 2023-12-12 |
| A Trial of SHR-1701 in Subjects With Advanced Solid Tumors SHR-1701 - Advanced Solid Tumor | Phase 1 | Completed | Atridia Pty Ltd. | 41 | 2020-03-31 | 2023-02-21 |
| SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma SHR-1701, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 91 | 2020-03-27 | 2021-12-21 |
| SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors SHR-1701 - Solid Tumor | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 193 | 2019-01-24 | 2022-11-08 |
| SHR-1701 in Metastatic or Locally Advanced Solid Tumors SHR-1701 - Solid Tumor | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 206 | 2018-11-20 | 2021-11-22 |
Nasopharyngeal Carcinoma (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Hodgkin Disease (1) · Lymphoma (1)
Jiangsu HengRui Medicine Co., Ltd. (6) · Chinese PLA General Hospital (2) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (2) · Atridia Pty Ltd. (1) · West China Hospital (1)
China (10) · Australia (1)
Dan Cao (1) · Jifeng Feng, MD (1) · Lin Shen, MD (1) · Weidong Han, PhD (1)